Description
•Targeted specificity to 100% of currently available
complete genomes for SARS-CoV-2
• Assays target spike (S) protein and nucleocapsid (N) protein regions having higher specificity and exhibiting lower risk for mutation
• Applied Biosystem COVID-19 Interpretive Software, which automatically converts genetic analysis data into diagnosis, helping reduce risk of user interpretation error
• Six approved specimen types, requiring only 200 to 400 µL of sample: bronchoalveolar lavage (BAL), mid-turbinate swabs, nasal swabs, nasopharyngeal swabs, nasopharyngeal aspirate (nasal aspirate), and oropharyngeal swabs